Endocrine Abstracts

Objective: To evaluate the results of the early postoperative low-dose (1 μg) ACTH (adrenocorticotropin) stimulation test in patients with Cushing’s disease (CD) in order to predict long-term outcome of transsphenoidal surgery.Methods: We reviewed the serum cortisol response to 1 μg synthetic ACTH (1–24) in the second week after pituitary surgery in 40 patients with Cushing’s disease. Median follow-up was 48.5 months (range 6&#15...

Background: Testosterone (T) in a hydroalcoholic gel is commonly prescribed as androgen replacement therapy and may not be accompanied by peaks and troughs of serum T levels as seen in T-injectables. We assessed in 17 subjects the differences in serum testosterone (sT) and free T (fT) levels during four different application periods.Methods: Patients where on daily 50 mg Androgel®, for 7 consecutive days in each cycle, on day 8 serum was ...

Introduction: Craniopharyngiomas are benign tumors in the suprasellar region that have encouraging survival rates between 77-93%. Unfortunately, long-term sequelae are frequent, resulting in excessive endocrine and metabolic morbidity, including premature cardiovascular disease and reduced bone health.Objective: To determine the prevalence of unfavorable body composition and low bone mineral density (BMD) in patients with craniopharyngioma.<p class="...

BackgroundFeatures of Prader-Willi syndrome (PWS) overlap with features of growth hormone (GH) deficiency, like small hands and feet, short stature, increased body fat and low muscle mass and strength. In children with PWS, GH treatment improves physical health, cognition and quality of life (QoL). GH treatment is standard of care in PWS children, but in adults this is not the case. A systematic review and meta-analysis was conducted to provide a concise...

IntroductionPrader-Willi syndrome (PWS) is a complex genetic syndrome in which hypothalamic dysfunction leads to hyperphagia and pituitary hormone deficiencies (PHD), among others. The majority of patients have intellectual disability (ID) and use of psychotropic drugs is frequent. Due to hypotonia and the low muscle mass associated with the syndrome, adults with PWS have a low basal metabolic rate (BMR). Combined with hyperphagia, this results in high r...

Background: Prader-Willi syndrome (PWS) is a complex rare genetic disorder associated with hypothalamic dysfunction, pituitary hormone deficiencies, hyperphagia and (morbid) obesity. PWS is caused by loss of expression of paternally expressed genes on chromosome 15q11.2-q13. The most common genetic mechanisms leading to PWS are paternal deletion (DEL) and maternal uniparental disomy (mUPD). DELs can be subdivided in type 1 and (smaller) type 2 deletions (DEL-1, DEL-2). Most re...

Objective: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with endocrinopathies, which may potentially impair bone health. Our objective was to determine bone health status in CP patients.Methods: In this retrospective study, Dutch/Swedish CP patients were included if data was available on fractures, bone mineral density (BMD) (T/Z-score), or final height (age >18 years). Data is presented as mean±<s...

Background: Previous studies indicate that PAS-LAR can achieve control of insulin-like growth factor I (IGF-I) levels and may reduce tumor size, however a subset of acromegaly patients responds poorly. T2-signal intensity, somatostatin receptor (SST) subtype 2 and 5 expression, and the response to first-generation somatostatin receptor ligands (SRLs) are recognized predictors of therapy response. Valid prediction of the response to PAS-LAR can alter treatment stratification.</...

Background: Prolactinomas are the most frequent secreting pituitary adenomas encountered in the clinical setting. Cabergoline is considered the mainstay medical treatment and transsphenoidal surgery (TSS) is recommended for patients that are medically resistant to dopamine agonist therapy. Resistance to dopamine agonists is commonly defined as failure to normalize prolactin and less than 50% decrease in tumor diameter at a maximal labeled dose of 2.0 mg/week. Pasireotide LAR (...

Introduction: Patients with craniopharyngioma (CP) suffer from pituitary deficiencies and hypothalamic damage, resulting in obesity and impaired bone health. Little is known about long-term changes in body composition and bone mineral density (BMD).Methods: Dutch and Swedish patients were included in this retrospective longitudinal study if they had DXA-scan (body composition/BMD) data available at age of 18 years or older. Linear regression modelswerees...